Oslo, Norway, 16 April 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or the "Company") on 26 January 2026 regarding the extraordinary general meeting held the same day, at which it was resolved, inter alia, to convert the Company from a private limited liability company (AS) to a public limited liability company (ASA).
The conversion and the change of the Company's name to "Lytix Biopharma ASA" has today been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret).
Disclosure regulation:
This information is subject to a duty of disclosure pursuant to the Company's continuing obligations as a company listed on Euronext Growth.
For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com
About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.